Skip to main content

Table 3 Criteria for drug withdrawal and re-administration

From: Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial

Drug withdrawal

Neutrophil

Level 3 or 4

Platelet

Level 3 or 4

Serum creatinine

1.5 times over the upper limit of normal value (44–132 μM)

Infection

Infectious fever with temperature > 38 °C

Diarrhea, mouth ulcers

Level 3 or 4

Others

When adverse reactions occur in addition to the above, and the investigators cannot judge whether drug administration can be continued or not, the drug will be discontinued

Drug re-administration

Neutrophil

> 1.0 × 109/L

Platelet

> 50 × 109/L

Serum creatinine

< the upper limit of normal value (44–132 μM)

Infection

No infectious fever

Diarrhea, mouth ulcers

≤ Level 1

Others

When adverse reactions leading to drug withdrawal are alleviated or disappear, the administration can be resumed as determined by the investigators

  1. Drug withdrawal and re-administration will be assessed using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 430